David McDonnell, MD

Alkermes Pharma Ireland Ltd, Dublin, Ireland

  • 7Articles
  • 58.1KReads
  • 2008–2026Active
  • 29Collaborators
  • 95Citations

About

David McDonnell, MD, is affiliated with Alkermes Pharma Ireland Ltd in Dublin, Ireland. His publications from 2008 to 2026 focus on schizophrenia, schizoaffective disorders, bipolar disorder, and weight-related effects of treatments. He has contributed to clinical research on olanzapine combined with samidorphan, examining efficacy, safety, tolerability, and weight gain in various patient populations, including those with early illness and comorbid alcohol use disorder. His frequent collaborators include Christoph U. Correll, Adam Simmons, Christina Arevalo, Bernard L. Silverman, and Lauren DiPetrillo.

Publications

JCP
Efficacy of Olanzapine/Samidorphan on Negative Symptoms
Original Research

Efficacy of Olanzapine/Samidorphan on Negative Symptoms

March 9, 2026

Olanzapine/samidorphan was associated with significant and durable improvement in negative symptoms of schizophrenia, overall and among patients with prominent and predominant negative symptoms.
, , , et al
JCP
Olanzapine/Samidorphan Effects on Weight Gain
Original Research

Olanzapine/Samidorphan Effects on Weight Gain

January 2, 2025

Treatment with a combination of olanzapine and samidorphan was associated with less weight gain and reduced risk of reaching ≥7% or ≥10% gain in body weight versus olanzapine over...
, , , et al
JCP
Long-Term Safety and Treatment Effect of Olanzapine/Samidorphan
Original Research

Long-Term Safety and Treatment Effect of Olanzapine/Samidorphan

December 4, 2024

During up to 4 years of treatment, the combination of olanzapine/samidorphan was safe and well-tolerated, and patients’ symptoms remained stable.
, , , et al
JCP
Olanzapine/Samidorphan Mitigates Weight Gain in Early Illness
Original Research

Olanzapine/Samidorphan Mitigates Weight Gain in Early Illness

March 22, 2023

In patients with early-phase schizophrenia or bipolar disorder, combination olanzapine and samidorphan resulted in less weight gain at week 12 than olanzapine alone. Antipsychotic efficacy was similar between the...
, , , et al
JCP
Original Research

Olanzapine Plus Samidorphan in Schizophrenia With AUD

March 10, 2020

Alcohol use disorder is comorbid in 33% of US patients with schizophrenia. Testing the tolerability of olanzapine and samidorphan until the first event of exacerbation of disease symptoms is...
, , , et al
JCP
Original Research

Olanzapine/Samidorphan for Schizophrenia

March 3, 2020

Read a study evaluating the antipsychotic efficacy and safety of OLZ/SAM compared with placebo in patients with an acute exacerbation of schizophrenia.
, , , et al
JCP
Original Research

An 8-Week, Double-Blind, Randomized, Placebo-Controlled Study of Olanzapine Long-Acting Injection in Acutely Ill Patients With Schizophrenia

May 11, 2008

, , , et al

Physicians Postgraduate Press, Inc. (PPP) makes no warranties about the accuracy or completeness of any information published in The Journal of Clinical Psychiatry or other PPP materials, and disclaims liability for any use or non-use of that information. Clinicians should not rely solely on these materials and should exercise their own professional judgment when making patient care decisions on an individualized basis.

Learn More About Psychedelics in Psychiatry

Explore the Collection
Neural network illustration symbolizing psychedelic research advancements

Subscribe to read
more articles

Subscribe